Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema

Retina

Volumn 31, Issue 1, 2011, Pages 111-118

  Bae, Jeong Hun ^a   Lee, Christopher Seungkyu ^b   Lee, Sung Chul ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

bevacizumab; cystoid macular edema; triamcinolone acetonide; uveitis

Indexed keywords

ACETAZOLAMIDE; ALPHA INTERFERON; ANTIGLAUCOMA AGENT; AZATHIOPRINE; BEVACIZUMAB; CORTICOSTEROID; CYCLOSPORIN A; LEVOFLOXACIN; TAMCETON; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CATARACT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; LENS DISEASE; MALE; PTOSIS; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA CYSTOID EDEMA; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TENON CAPSULE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; UVEITIS; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 78651346529     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181e378af     Document Type: Article

References (30)

1. Rothova A, Suttorp-van SchultenMS, Frits TreffersW, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336.
2. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113: 1446-1449.
3. Gurlu VP, Alimgil ML, Esgin H. Fluorescein angiographic findings in cases with intermediate uveitis in the inactive phase. Can J Ophthalmol 2007;42:107-109.
4. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916.e1-1916.e7.
5. Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 2005;13:205-212.
6. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbort CP. Posterior sub-Tenon steroid injections for the treatment of posterior ocular inflammation: Indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999;237: 289-295.
7. Avery RL, Pieramici DJ, RabenaMD, Castellarin AA, NasirMA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113: 363-372.
8. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
9. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
10. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol 2007;125:751-756.
11. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-1579.
12. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study. Retina 2008;28:41-45.
13. Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye 2009;23:1812-1818.
14. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2004;111:946-953.
15. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007;245:917-918.
16. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007;18:487-492.
17. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-796.
18. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-294.
19. Ozdek S, Bahceci UA, Gurelik G, Hasanreisoglu B. Posterior sub-Tenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complications 2006;20:246-251.
20. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or sub-Tenon injection. Am J Ophthalmol 2004;138:1046-1048.
21. Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior sub-Tenon injection. Ocul Immunol Inflamm 2008;16:217-223.
22. Fine BS, Brucker AJ. Macular edema and cystoid macular edema. Am J Ophthalmol 1981;92:466-481.
23. Tso MO. Pathology of cystoid macular edema. Ophthalmology 1982;89:902-915.
24. Sivaprasad S, Ikeji F, Xing W, Lightman S. Tomographic assessment of therapeutic response to uveitic macular oedema. Clin Experiment Ophthalmol 2007;35:719-723.
25. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
26. van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 2006;14: 73-85.
27. Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-881.
28. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet syndrome. Int J Dermatol 2003; 42:870-875.
29. Atmaca LS, Batioglu F, Idil A. Retinal and disc neovascularization in Behcet disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 1996;234:94-99.
30. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.